CLAUDIA GOLDENSTEIN SCHAINBERG
Projetos de Pesquisa
Unidades Organizacionais
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
33 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 33
conferenceObject Behcet's Disease Activity: An Important Factor For Immunogenicity Of Unadjuvanted Influenza A/H1N1 Vaccine(2013) PRADO, Leandro L.; SAAD, Carla G. S.; MORAES, Julio C. B.; RIBEIRO, Ana Cristina Medeiros; AIKAWA, Nadia E.; SILVA, Clovis A.; SCHAINBERG, Claudia G.; SAMPAIO-BARROS, Percival D.; PRECIOSO, Alexander R.; ISHIDA, Maria A.; BONFA, Eloisa; GONCALVES, CelioconferenceObject OBSERVATIONAL STUDY OF SWITCHING ANTI-TNF AGENTS IN ANKYLOSING SPONDYLITIS: EFFECTIVENESS AND PREDICTORS(2014) SAAD, C. G. S.; SHIMABUCO, A. Y.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C.; BONFA, E.- HIGH RATES OF WORK DISABILITY IN PATIENTS WITH PSORIATIC ARTHRITIS(2015) GASPARI, C. N. De; GOLDEINSTEIN-SCHAINBERG, C.; PRETTI, F. Z.; SILVA, T. C. P.; GONCALVES, C. R.; SAMPAIO-BARROS, P. D.; SAAD, C. G. S.; MORAES, J. C. B.
conferenceObject A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDYLOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINICAL AND TREATMENT DATA(2018) SHIMABUCO, A.; MORAES, J. C. B. de; SAMPAIO-BARROS, P.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C. R.; SAAD, C. G. S.conferenceObject INFLUENCE OF SULFASALAZINE COMEDICATION IN SWITCHING AND RESPONSE TO ANTI-TUMORAL NECROSIS FACTOR IN ANKYLOSING SPONDYLITIS(2016) SHIMABUCO, A. Y.; GONCALVES, C. R.; MORAES, J. C. B.; WAISBERG, M. G.; RIBEIRO, A. C. M.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; BONFA, E.; SAAD, C. G. S.bookPart Espondiloartrites: Outras(2016) GONçALVES, Célio Roberto; SCHAINBERG, Cláudia Goldenstein; MORAES, Julio César Bertacini deconferenceObject Metabolic Syndrome in Patients with Psoriatic Arthritis Is Associated to Peripheral Disease Activity(2015) GASPARI, Camilla De; MORAES, Julio C. B.; SAMPAIO-BARROS, Percival D.; GONCALVES, Celio R.; SAAD, Carla G. S.; GOLDENSTEIN-SCHAINBERG, Claudia- Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area(2020) SHIMABUCO, Andrea Yukie; MEDEIROS-RIBEIRO, Ana Cristina de; MIOSSI, Renata; BONFIGLIOLI, Karina Rossi; MORAES, Julio Cesar Bertacini de; GONCALVES, Celio Roberto; SAMPAIO-BARROS, Percival Degrava; GOLDENSTEIN-SCHAINBERG, Claudia; SOUZA, Fernando Henrique Carlos de; PRADO, Leandro Lara do; UGOLINI-LOPES, Michele Remiao; YUKI, Emily Figueiredo Vieira Neves; BONFA, Eloisa; SAAD, Carla Goncalves SchahinOBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-exposure and other risk factors for TB development. METHODS: A total of 135 and 83 patients with AS and PsA, respectively, were evaluated for LTBI treatment before receiving anti-TNF drugs via the tuberculin skin test (TST), chest radiography, and TB exposure history assessment. All subjects were evaluated for TB infection at 3-month intervals. RESULTS: The patients with AS were more often treated for LTBI than were those with PsA (42% versus 30%, p=0.043). The former also presented a higher frequency of TST positivity (93% versus 64%, p=0.002), although they had a lower frequency of exposure history (18% versus 52%, p=0.027) and previous TB (0.7% versus 6%, p=0.03). During follow-up [median, 5.8 years; interquartile range (1QR), 2.2-9.0 years], 11/218 (5%) patients developed active TB (AS, n=7; PsA, n=4). TB re-exposure was the main cause in seven patients (64%) after 12 months of therapy (median, 21.9 months; IQR, 14.2-42.8 months) and five LTBI-negative patients. TB was identified within the first year in four patients (36.3%) (median, 5.3 months; IQR, 1.2-8.8 months), two of whom were LTBI-positive. There was no difference in the TB-free survival according to the anti-TNF drug type/class; neither synthetic drug nor prednisone use was related to TB occurrence (p > 0.05). CONCLUSION: Known re-exposure is the most critical factor for incident TB cases in spondyloarthritis. There are also some distinct features in AS and PsA LTBI screening, considering the higher frequency of LTBI and TST positivities in patients with AS. Annual risk reassessment taking into consideration these peculiar features and including the TST should be recommended for patients in endemic countries.
conferenceObject HLA-B27 PREVALENCE IN A COHORT OF BRAZILIAN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS(2014) GOLDENSTEIN-SCHAINBERG, C.; CARRASCO, S.; SAAD, C. G.; MORAES, J. C. B.; GONCALVES, C. R.; SAMPAIO-BARROS, P.; PARRA, E. R.- SARS-COV-2 VACCINE IN SPONDYLOARTHRITIS PATIENTS: OVERALL MODERATE/HIGH IMMUNOGENICITY IMPAIRED BY IMMUNOSUPPRESSANTS AND BIOLOGICAL THERAPY(2022) SAAD, C.; SILVA, M. Rodrigues; SAMPAIO-BARROS, P. Degrava; MORAES, J.; GOLDENSTEIN-SCHAINBERG, C.; AIKAWA, N.; NEVES, E.; PASOTO, S.; PEDROSA, T.; AOYAMA, R. Kenji; ARAUJO, C. Scognamiglio Renner; SILVA, C.; RIBEIRO, A. C. Medeiros; BONFA, E.